AI Article Synopsis
- Used 1,4-dibromonaphthalene (1,4-DBN) as a precursor molecule on an Ag(111) surface to explore various structures via low-temperature scanning tunneling microscopy.
- Identified three ordered phases (I, II, III) and one metal-organic short-chain structure (phase IV) at high coverage, along with a new chiral structure (phase V) at low coverage, all incorporating surface Ag adatoms.
- Demonstrated that a dissymmetric dehalogenation reaction leads to phase III, and thermal annealing promotes Ullmann coupling and cyclodehydrogenation of 1,4-DBN, creating armchair-shaped graphene nanoribbons, with surface
Article Abstract
Herein, using 1,4-dibromonaphthalene (1,4-DBN) as the precursor molecule and Ag(111) surface as the substrate, we have characterized the various coordination and covalent structures formed by 1,4-DBN by low-temperature scanning tunnelling microscopy. We observed that there are three ordered structures (phase I, II, III) and one metal-organic short-chain structure (phase IV) at high coverage, meanwhile a new type of chiral structure (phase V) is observed coexisting with phase II, III, IV at low coverage. Surprisingly, all these structures have surface Ag adatoms incorporated. In addition, the phase III should be formed by a dissymmetric dehalogenation reaction of 1,4-DBN. Furthermore, we showed that the Ullmann coupling and cyclodehydrogenation of 1,4-DBN to form the armchair-shaped graphene nanoribbons will occur after thermal annealing. Combining the experiment data and density functional theory simulations, our results show that the surface Ag adatoms play a critical role in both the self-assembly and the on-surface reaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/asia.202300136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Blood
January 2025
Stanford University Medical Center, Stanford, California, United States.
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity.We enrolled 44 patients on an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg cell therapy manufactured from donor mobilized peripheral blood improves one-year GVHD-free relapse free survival (GRFS) after myeloablative conditioning (trial NCT01660607).
View Article and Find Full Text PDFPolatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.
J Cancer Res Ther
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Background: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.
Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
CNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFGanaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder.
Paediatr Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral ganaxolone (ZTALMY), a synthetic analogue of the endogenous neuroactive steroid allopregnanolone, acts as a positive allosteric modulator of synaptic and extra-synaptic γ-aminobutyric acid (GABA) type A receptor function in the CNS. In the EU and the UK, it is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2-17 years. In a multinational phase III study (Marigold), 17 weeks' therapy with adjunctive ganaxolone, administered orally three times daily with food, significantly reduced 28-day major motor seizure frequency from baseline versus placebo in patients aged 2-19 years with CDD-associated refractory epilepsy.
View Article and Find Full Text PDFWhat is the Surgical Burden of Treatment for High-Energy Lower Extremity Trauma? A Secondary Analysis of the OUTLET Study.
J Orthop Trauma
January 2025
Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco, CA.
Objectives: To describe and enumerate surgeries for patients who underwent reconstruction or amputation after severe distal tibia, ankle, and mid to hindfoot injuries.
Methods: Design: Secondary analysis of a multicenter prospective observational study.
Setting: 31 U.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!